The Lancet Gastroenterology & Hepatology· Mazen Noureddin, Winston Dunn, Rashmee Patil, Dimple Desai, Rohit Puskoor, Jaehee Shin, Dennis To, Adam C Bell, Daniel R Lee, Yen-Huei Lin, Seulki Lee·· 2026-07-22AI 评分56
DD01双受体激动剂治疗MASLD和脂肪性肝炎:II期随机对照试验12周结果
[Articles] The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial
AI 导读
DD01-DN-02是一项随机、双盲、多中心、安慰剂对照的II期试验,评估胰高血糖素与GLP-1受体双激动剂DD01用于代谢功能障碍相关脂肪性肝病和脂肪性肝炎。预设的12周主要分析显示,与安慰剂相比,DD01使肝脏脂肪快速下降,研究者认为这支持开展长期研究进一步评估。
来源:The Lancet Gastroenterology & Hepatology · thelancet.com